Obesity

Exploring FDA-approved GLP-1 receptor agonists

May 14, 2024 - Glucagon-like peptide-1 (GLP-1) receptor agonists, also called incretin mimetics, are a class of medications that mimic the effects of incretin hormones. These medications stimulate the body's GLP-1 receptors, which help regulate blood sugar levels and promote weight loss. GLP-1 receptor agonists are primarily delivered via subcutaneous injections, such as liquid medication...

Read More


More Articles

Exploring the top 20 biopharma companies Q1 2024 market cap growths

by Alivia Kaylor

In the midst of economic uncertainties, fluctuating interest rates, and evolving Medicare Drug Price Negotiation policies, the top 20 global biopharmaceutical companies have achieved a promising start to the year. According to a GlobalData...

Addressing muscle loss associated with GLP-1 medication use

by Veronica Salib

Glucagon-like peptide-1 (GLP-1) receptor agonists — also known as GLP-1 drugs — have gained a significant amount of attention in recent years because of their utility in managing type 2 diabetes (T2D) and, even more so, in...

Eli Lilly partners with Amazon Pharmacy to deliver GLP-1 drugs

by Veronica Salib

Amazon Pharmacy will now be filling prescriptions for glucagon-like peptide-1 (GLP-1) drugs — and other pharmaceuticals for obesity, diabetes, and migraines — requested through Eli...

FDA expands Wegovy indications, adding cardiovascular disease

by Veronica Salib

On March 8, 2024, the United States FDA expanded approval of Wegovy (semaglutide), making it the first weight loss drug that is FDA-approved for obese and overweight patients at high risk for heart...

Mayo Clinic Launches Weight Loss Prescription Program

by Veronica Salib

On January 16, 2024, the Mayo Clinic Diet, a weight loss program developed and approved by the Mayo Clinic, announced the beta launch of the Mayo Clinic Diet Medical Weight Loss Rx Program. The growing...

Lilly Launches Digital Obesity, Migraine, Diabetes Management Platform

by Veronica Salib

Yesterday, January 4, 2024, Eli Lilly and Company issued a press release announcing the launch of LillyDirect. The platform is a digital healthcare tool for managing and supporting patients with...

Semaglutide Reduces Weight in Patients with Failed Bariatric Surgery

by Veronica Salib

According to a study published in Obesity, semaglutide effectively triggers weight loss in severely obese patients, including those who have had bariatric surgery to manage weight but have not yielded...

Roche Expands Obesity Portfolio Through $2.7 Billion Carmot Acquisition

by Veronica Salib

On December 4, 2023, Roche revealed that it entered into definitive merger agreements with Carmot Therapeutics. According to the company’s press release, it will acquire Carmot and its gamut of...

FDA Approves New Weight Loss Drug: Zepbound

by Veronica Salib

On November 8, 2023, the United States Food and Drug Administration (FDA) approved Eli Lilly’s newest weight loss drug, Zepbound. The newly approved drug uses the same active ingredient as...

Are Therapeutic Advancements Impacting the Demand for Surgery?

by Veronica Salib

According to the 2023 Trilliant Health report on trends shaping the health economy, the overall demand for surgical procedures has declined from 2017 to 2021. Despite declining rates of surgical interventions, the national disease burden...

Psychiatrists Prescribe or Recommend Ozempic, Other Weight Loss Drugs

by Veronica Salib

On November 3, 2023, the New York Times broke a story analyzing the role of Ozempic and other weight loss drugs in mental health or psychiatric care. Upon reaching out to 13 psychiatric departments at...

Online Vendors Sell Unapproved GLP-1 Drugs, FDA Issues Warnings

by Veronica Salib

Last week, the United States Food and Drug Administration (FDA) issued two warning letters to online vendors selling unauthorized versions of semaglutide and tirzepatide, active ingredients in...

Semaglutide Treatment Reduces Heart Failure Symptoms in Obese Patients

by Veronica Salib

Yesterday, the New England Journal of Medicine published the results of a randomized study, which revealed that semaglutide can help manage heart failure symptoms in obese patients with preserved...

Ozempic in the US Costs Over Five Times More Than in Other Countries

by Veronica Salib

As weight loss drugs like Ozempic, Wegovy, and Mounjaro become increasingly popular in the United States, the financial weight of these drugs poses a significant burden for the US healthcare system....

Majority of Patients Quit Weight-Loss Drugs Like Wegovy Within First Year

by Hayden Schmidt

A recent cost analysis shared with Reuters showed that only a third of patients continued to use popular glucagon-like peptide-1 (GLP-1) compounds a year after initial prescription. Healthcare costs...

Guiding Obesity Management by Understanding Weight Loss Drugs

by Veronica Salib

As the popularity of weight management drugs, including Ozempic, continues to rise, clinicians and healthcare professionals need a guide to the obesity drug landscape. The nuanced field of weight management continues to become more and...

Retatrutide Helps Patients Achieve 17.5% Weight Reduction at 24 Weeks

by Veronica Salib

A phase 2 clinical trial published in the New England Journal of Medicine revealed that retatrutide, Eli Lilly’s newest weight loss drug, helped patients achieve a 17.5% weight reduction in 24...

FDA Issues Warning on Compounded Semaglutide Products

by Veronica Salib

Compounded forms of semaglutide have been linked to adverse events, leading to FDA-issued warnings. As a result, the FDA recommends that patients avoid compounded semaglutide whenever the approved...

Researchers Explore Ozempic as a Potential Addiction Treatment

by Veronica Salib

Gaining popularity from celebrity endorsements and public speculation, Ozempic has become a staple weight loss drug in the United States. However, researchers speculate that the medication could...

Recent Articles